Jefferies Group LLC reiterated their hold rating on shares of Qiagen N.V. (NASDAQ:QGEN) in a research note issued to investors on Monday morning. They currently have a $28.00 target price on the stock, up from their prior target price of $25.00. Jefferies Group also issued estimates for Qiagen N.V.’s Q3 2017 earnings at $0.31 EPS, FY2017 earnings at $1.18 EPS, FY2018 earnings at $1.38 EPS, FY2019 earnings at $1.54 EPS, FY2020 earnings at $1.70 EPS and FY2021 earnings at $1.87 EPS.

A number of other equities research analysts also recently commented on QGEN. BidaskClub raised Qiagen N.V. from a hold rating to a buy rating in a report on Wednesday, July 19th. Deutsche Bank AG reissued a buy rating on shares of Qiagen N.V. in a report on Monday. TheStreet downgraded Qiagen N.V. from a b rating to a c+ rating in a report on Thursday, July 27th. Barclays PLC reissued an overweight rating and issued a $37.00 target price (up previously from $33.00) on shares of Qiagen N.V. in a report on Monday, July 17th. Finally, Commerzbank Ag reissued a buy rating on shares of Qiagen N.V. in a report on Friday, July 28th. Seven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Qiagen N.V. currently has an average rating of Hold and an average price target of $33.19.

Qiagen N.V. (NASDAQ QGEN) traded down 0.80% during trading on Monday, hitting $32.11. 667,257 shares of the stock traded hands. The stock has a market cap of $7.33 billion, a P/E ratio of 98.20 and a beta of 1.14. The firm’s 50-day moving average is $33.97 and its 200-day moving average is $31.03. Qiagen N.V. has a 12 month low of $24.86 and a 12 month high of $35.26.

Qiagen N.V. (NASDAQ:QGEN) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The firm had revenue of $349 million during the quarter, compared to the consensus estimate of $353.09 million. During the same period last year, the company earned $0.24 earnings per share. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, analysts forecast that Qiagen N.V. will post $1.21 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/08/04/qiagen-n-v-qgen-receives-hold-rating-from-jefferies-group-llc.html.

Several hedge funds and other institutional investors have recently made changes to their positions in QGEN. Hussman Strategic Advisors Inc. purchased a new position in shares of Qiagen N.V. during the first quarter worth $3,540,000. Canada Pension Plan Investment Board boosted its position in shares of Qiagen N.V. by 1,128.0% in the first quarter. Canada Pension Plan Investment Board now owns 481,483 shares of the company’s stock worth $14,012,000 after buying an additional 442,274 shares in the last quarter. Exane Derivatives boosted its position in shares of Qiagen N.V. by 427.6% in the first quarter. Exane Derivatives now owns 82,944 shares of the company’s stock worth $2,413,000 after buying an additional 67,224 shares in the last quarter. Wetherby Asset Management Inc. boosted its position in shares of Qiagen N.V. by 1.8% in the first quarter. Wetherby Asset Management Inc. now owns 9,273 shares of the company’s stock worth $269,000 after buying an additional 163 shares in the last quarter. Finally, First Mercantile Trust Co. boosted its position in shares of Qiagen N.V. by 27.3% in the first quarter. First Mercantile Trust Co. now owns 14,593 shares of the company’s stock worth $422,000 after buying an additional 3,126 shares in the last quarter. Institutional investors and hedge funds own 60.45% of the company’s stock.

Qiagen N.V. Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.